JP2024517607A5 - - Google Patents
Info
- Publication number
- JP2024517607A5 JP2024517607A5 JP2023562936A JP2023562936A JP2024517607A5 JP 2024517607 A5 JP2024517607 A5 JP 2024517607A5 JP 2023562936 A JP2023562936 A JP 2023562936A JP 2023562936 A JP2023562936 A JP 2023562936A JP 2024517607 A5 JP2024517607 A5 JP 2024517607A5
- Authority
- JP
- Japan
- Prior art keywords
- sequence
- nuclease system
- manipulated
- nucleic acid
- endonuclease
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202163182438P | 2021-04-30 | 2021-04-30 | |
| US63/182,438 | 2021-04-30 | ||
| PCT/US2022/027124 WO2022232638A2 (en) | 2021-04-30 | 2022-04-29 | Enzymes with ruvc domains |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2024517607A JP2024517607A (ja) | 2024-04-23 |
| JP2024517607A5 true JP2024517607A5 (enExample) | 2025-05-01 |
Family
ID=83847352
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023562936A Pending JP2024517607A (ja) | 2021-04-30 | 2022-04-29 | Ｒｕｖｃドメインを有する酵素 |
Country Status (10)
| Country | Link |
|---|---|
| US (1) | US20240110167A1 (enExample) |
| EP (1) | EP4330386A4 (enExample) |
| JP (1) | JP2024517607A (enExample) |
| KR (1) | KR20240004618A (enExample) |
| CN (1) | CN117203332A (enExample) |
| AU (1) | AU2022264921A1 (enExample) |
| BR (1) | BR112023022270A2 (enExample) |
| CA (1) | CA3214222A1 (enExample) |
| MX (1) | MX2023012606A (enExample) |
| WO (1) | WO2022232638A2 (enExample) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2022335499A1 (en) | 2021-08-27 | 2024-02-22 | Metagenomi Therapeutics, Inc. | Enzymes with ruvc domains |
| AU2022396533A1 (en) | 2021-11-24 | 2024-05-02 | Metagenomi Therapeutics, Inc. | Endonuclease systems |
| WO2025059585A1 (en) * | 2023-09-13 | 2025-03-20 | Metagenomi, Inc. | Engineered and chimeric nucleases |
| WO2025106934A1 (en) * | 2023-11-16 | 2025-05-22 | Metagenomi, Inc. | Enzymes with ruvc domains |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN113355357B (zh) * | 2012-12-12 | 2024-12-03 | 布罗德研究所有限公司 | 对用于序列操纵的改进的系统、方法和酶组合物进行的工程化和优化 |
| US9234213B2 (en) * | 2013-03-15 | 2016-01-12 | System Biosciences, Llc | Compositions and methods directed to CRISPR/Cas genomic engineering systems |
| SG11201906297QA (en) * | 2017-03-24 | 2019-10-30 | Curevac Ag | Nucleic acids encoding crispr-associated proteins and uses thereof |
| WO2019165168A1 (en) * | 2018-02-23 | 2019-08-29 | Pioneer Hi-Bred International, Inc. | Novel cas9 orthologs |
| CA3241703C (en) * | 2019-02-14 | 2026-02-24 | Metagenomi Therapeutics, Inc. | Enzymes with ruvc domains |
| US10913941B2 (en) * | 2019-02-14 | 2021-02-09 | Metagenomi Ip Technologies, Llc | Enzymes with RuvC domains |
-
2022
- 2022-04-29 KR KR1020237040583A patent/KR20240004618A/ko active Pending
- 2022-04-29 CN CN202280030364.7A patent/CN117203332A/zh active Pending
- 2022-04-29 EP EP22796888.0A patent/EP4330386A4/en active Pending
- 2022-04-29 JP JP2023562936A patent/JP2024517607A/ja active Pending
- 2022-04-29 WO PCT/US2022/027124 patent/WO2022232638A2/en not_active Ceased
- 2022-04-29 BR BR112023022270A patent/BR112023022270A2/pt unknown
- 2022-04-29 CA CA3214222A patent/CA3214222A1/en active Pending
- 2022-04-29 AU AU2022264921A patent/AU2022264921A1/en active Pending
- 2022-04-29 MX MX2023012606A patent/MX2023012606A/es unknown
-
2023
- 2023-10-17 US US18/488,520 patent/US20240110167A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2024517607A5 (enExample) | ||
| JP2022520428A5 (enExample) | ||
| JP2024535672A5 (enExample) | ||
| US20230123754A1 (en) | RNA-DIRECTED DNA CLEAVAGE BY THE Cas9-crRNA COMPLEX | |
| JP2022552409A5 (enExample) | ||
| CA3128755C (en) | Compositions and methods for treating hemoglobinopathies | |
| JP2023542976A5 (enExample) | ||
| JP2022531347A5 (enExample) | ||
| JP2020512845A5 (enExample) | ||
| JP2023519953A5 (enExample) | ||
| JP2025160487A5 (enExample) | ||
| JP2024038327A5 (enExample) | ||
| JP6219944B2 (ja) | ５’保護に依存した増幅 | |
| JP2023533417A5 (enExample) | ||
| JP2021532815A5 (enExample) | ||
| JP2024533940A5 (enExample) | ||
| JP2021530988A5 (enExample) | ||
| JP2024541402A5 (enExample) | ||
| JP2002519038A5 (enExample) | ||
| US20230357790A1 (en) | Self-targeting expression vector | |
| JP2024500036A5 (enExample) | ||
| JP2021526798A5 (enExample) | ||
| JP2020536506A5 (enExample) | ||
| US20250066752A1 (en) | Crispr-based programmable rna editing | |
| JP2023505188A5 (enExample) |